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BelgiumOsteoarthritis (OA) is presently one of the rapidly expand-
ing areas of research in the field of rheumatic diseases.
This is evidenced by the ever increasing number of publi-
cations concerning the clinical, structural and biochemical
manifestations of the disease. Effective medical treat-
ment of OA is now emerging as a plausible eventuality.
Distinction between symptom modifying OA drugs and
structure modifying OA drugs (STMOAD) has been recom-
mended1,2. Evaluation of STMOADs presents challenging
and exciting clinical trial methodologic issues. Guidelines
for clinical and radiographical evaluation in such trials have
been developed1–5. Biochemical markers of OA is another
rapidly developing field. The possibility of using such
markers as diagnosis or prognosis factors for OA, as well
as a method for assessment of progression of OA structural
changes has been proposed. As such, biochemical
markers may facilitate or enhance clinical evaluation of
STMOADs.
In 1996 the Osteoarthritis (OA) Section of the Group for
the Respect of Ethics and Excellence in Science (GREES)
published the first guidelines for the registration of drugs
used in the treatment of OA2. The quality and importance of
this first work performed by the experts of the GREES was
acknowledged by the Committee for Proprietary Medicinal289Products (CPMP) at the European Agency for Evaluation of
Medicines, which endorsed a number of their sugges-
tions. The issue of biochemical markers was only briefly
mentioned in the first GREES report. Thus, a working party
of the GREES convened in Vienna in September 1999 to
discuss whether biochemical markers of OA were appli-
cable to: (1) be used as surrogates for radiography for the
diagnosis of OA; (2) identify healthy individuals at risk for
the development of OA; (3) predict the outcome of OA in
the early stages of the disease in untreated or treated
patients, (4) assess progression of OA in untreated or
treated patients.Proposed biochemical markers of OA
OA is a structurally complex disease that comprises
cartilage destruction, subchondral bone sclerosis and
cysts, osteophytes and synovial inflammation. Cartilage
damage leading to progressive destruction of joint structure
is generally considered to be the most important lesion of
OA and most attention has been focused on this tissue.
However, markers of other joint tissues are also being
investigated as markers of OA.
Proteoglycans (PGs) and type II collagen are the major
constituents of cartilage. Various antibodies recognizing
nonspecified PG fragments, fragments containing either
keratan sulfate (5D4, AN9P1) or chondroitin sulfate
(3-B-3(-), 7-D-4, 846) and epitopes from the core proteinAddress correspondence and reprint requests to: Pr Eric Vignon,
Service de rhumatologie, Centre hospitalier Lyon-Sud, 69495
Pierre-Benite´ cedex, France. Tel: 04.78.86.12.20; Fax:
04.78.86.65.40; E-mail: eric.vignon@chu-lyon.fr
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Potential biochemical markers of osteoarthritis
Markers Tissue specificity Specificity
Collagen N/C propeptides Bone (type I) Formation
Cartilage (type II)
Synovium (type I, III)
Pyridinium cross-links None Degradation
Collagen N/C telopeptide Bone (type I) Degradation
Cartilage (type II)
Synovium (type I, III)
Type II collagen  chains collagenase epitopes Cartilage Degradation
Bone alkaline phosphatase Bone Formation
Osteocalcin Bone Formation
Bone sialoprotein Bone (subchondral) Mineralization ?
Proteoglycan fragments Cartilage ? Degradation ?
Keratan sulfate (5D4, AN9P1) Cartilage ? Degradation ?
Chondroitin sulfate (3B3, 846) Cartilage ? Formation ?
COMP None Degradation ?
Hyaluronan Synovium ? Inflammation ?
YKL-4O None Synovium inflammation
CRP None Synovium inflammation
MMPs and TIMPs None Synovium inflammation ?generated by metalloproteinases (MMPs) have been pro-
posed as markers of PG turnover. Assays of collagen
pyridinium cross-links, C/N telopeptides of type II collagen,
neoepitopes generated by the collagenase cleavage of
type II collagen and type II collagen propeptides (PII CP
and type IIA N propeptide) have been developed as
markers of cartilage collagen tunover. Other constituents of
the cartilage, such as the cartilage oligomeric matrix protein
(COMP), have also been suggested as markers of cartilage
destruction.
Other proposed markers of OA include markers of
synovial inflammation, such as C reactive protein (CRP),
hyaluronan, YKL-40, metalloproteases (MMPs) and MMP
inhibitors (TIMPs) and markers of bone turnover, such as
pyridinoline and bone sialoprotein (BSP). No specific
marker of osteophyte formation has yet been identified.
Current and potential markers of OA are listed in Table I.II collagen and type II collagen propeptides, respectively,
probably specifically reflect the degradation and the syn-
thesis of cartilage collagen. The significance, in terms
of formation/degradation, of other proposed markers of
cartilage, such as proteoglycan epitopes and COMP is less
clear.
To be applicable (‘valid’) in a certain setting, any
measure must be truthful, discriminative between con-
ditions of interest, and feasible in terms of cost, time and
interpretability6. In terms of truthfulness, validation of a
biochemical marker requires a good correlation between
a marker level in a sample fluid and biologic activity in
the tissue. Discrimination depends on the purpose of the
measurement: distinguishing between disease and nondis-
ease, assessing prognosis, or assessing change over time.
Study of applicability is quite difficult, particularly for articu-
lar cartilage. It might be helpful to consider joint tissues as
an organ and the synovial fluid (SF) as the biological
medium of the organ, i.e. to correlate between SF and
serum or urine findings. Assays and interpretation of
markers in the SF are especially difficult and SF collection
may often be technically or ethically difficult. Markers in SF
are probably valuable for evaluation of what is happening in
a target joint. Markers in blood and urine probably reflect
what is happening in multiple joints. Site and number of
joints to consider for accurate evaluation of blood and urine
markers remain a difficult question.
An increase in serum or urine of patients with knee or hip
OA has been reported for proteoglycan monomer frag-
ments7,8, 5D49–11, 3B3 and 84612–15, COMP11,16–20, C
telopeptide and neoepitope of type II collagen21,23, PII
CP24,25, hyaluronan26–28, CRP29,30, YKL-4031–33, MMPs34,
BSP30,35 and pyridinoline36–38. Decreased serum levels of
ANP9 have been reported in patients with primary OA11.
Conflicting results were obtained with pyridinoline37,38.
Most of the data generally have been obtained from
small cross-sectional studies. Thus, present knowledge
of the role of OA markers is limited. Technical validation
of a number of assays, as well as standardization or
centralization of the assays will also be necessary.Validation of biochemical markers in
osteoarthritis
The current list of potential or proposed markers of OA
includes none that is truly specific for the disease. Instead,
they reflect general remodeling of the various tissues of the
joint, cartilage, synovium and bone.
Tissue specificity should be a primary characteristic of a
biological marker. Some markers, such as bone alkaline
phosphatase, osteocalcin and BSP, can be regarded as
specific for bone turnover. Levels of D-pyridinoline and type
I collagen peptides reflect predominantly bone turnover.
Type II collagen markers are probably the most specific for
cartilagineous tissues including meniscus and interverte-
bral discs. Hyaluronan is accepted as a marker of the
synthetic activity of synovium. Other proposed markers
such as proteoglycan fragments, pyridinoline, COMP, CRP,
YKL-40, MMPs and TIMPs lack a clear specificity.
A meaningful biochemical marker must also specifically
reflect either the synthesis or the degradation of a tissue.
The specificity of markers for bone formation and bone
degradation is now well accepted. C/N telopeptides of type
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staging of OA patients
One of the problems in the study of markers is the fact
that there is no gold standard for the diagnosis of OA.
Current definitions of OA are based on clinical signs and/or
radiographical lesions. Thus, a biochemical marker could
be helpful to more precisely identify OA patients. As
mentioned above, no OA specific epitope has yet been
identified and proposed markers of OA are generic markers
of joint tissue remodeling. For example, COMP has been
proposed as a marker for an OA population20. However,
overlap between patients and healthy controls is generally
large enough to prevent the use of COMP or any current
marker on an individual patient basis. Moreover increased
levels of markers of cartilage, synovium or bone have been
found in various joint diseases other than OA39–42. Thus,
proposed markers cannot presently be considered as use-
ful for identification of OA patients. Similar considerations
and conclusions apply to the use of markers in identifying
future OA patients in a healthy population.
The use of biochemical markers for the staging of OA
patients is another question. Staging of OA can be made
according to the degree of pain or impairment or to the
degree of structural joint damage. Discordance between
symptoms and radiography is well known and grading is
generally based on structural change scores such as the
Kellgren and Lawrence. Variation of proteoglycan epitope
with joint space narrowing grade has been reported15,43.
An Increase in urine pyridinium cross-links of collagen in a
late X-ray stage of OA, a stage characterized by obvious
subchondral bone changes, has also been suggested36,38.
Synovium inflammation and hypertrophy is also known to
progress with duration of the disease. Thus, some markers,
alone or in combination, could possibly be helpful in the
future for the staging of OA.Biochemical markers as predictive factor for OA
progression
The high prevalence of OA is well known. However,
among patients with hip or knee OA only a relatively small
proportion of them develop progressive disease with
severe pain and disability, eventually justifying surgery.
Identification of patients at risk for such progression is
clearly of interest. The interest will probably increase in the
near future for cost/benefit analysis of potential STMOADs.
Increased levels of joint tissue markers, for cartilage deg-
radation especially, should theoretically be helpful. A pre-
dictive value for progression has been suggested for
COMP17–19, hyaluronan and CRP27,29,30. However, long-
term studies of cohorts evaluated with the use of modern
validated clinical and radiographical methods remain to be
performed.Biochemical markers for the assessment of OA
treatment
There is a potential utility of markers for the assessment
of OA progression in treated patients. For instance, a
marker of progressive cartilage destruction might allow
more rapid and more sensitive evaluation of a chondro-
protective treatment than is possible with radiographic
measurements spanning several years. Conversely, a
possible deleterious effect on cartilage degradation of aclinically effective treatment could also be detected more
rapidly. Markers of other joint tissues could also be rel-
evant. A correlation between BSP and OA progression has
been suggested35. Again, validation of markers for such a
purpose remains to be performed. This is a difficult task,
necessitating accurate clinical and radiographical measure-
ments in a large number of untreated patients and over a
long period.Conclusion
The present view on biochemical markers of OA might
appear pessimistic. However, it reflects the fact that
research in the field has only just started. Clearly, the group
underlined the multiple potential applications of biochemi-
cal markers of OA. Assaying specific markers of cartilage
degradation and synthesis, of bone remodeling and of
synovial inflammation will constitute important tools in
expanding our understanding of OA. At the present time,
identification, among current proposed markers, of the best
candidates is premature. Finally, the inclusion of patients
in the placebo group of long-term therapeutic trials is
essential to characterize the change of these markers over
time. All together, these data are likely to be critical for
validation of biochemical markers of OA.References
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